There has been considerable focus on the risks of hyperkalaemia, especially in patients with chronic kidney disease (CKD), diabetes mellitus, and/or heart failure. 1 -3 Although the exact level of serum potassium (K + ) that is associated with an increase in mortality remains controversial, increasing evidence suggests that in patients with CKD, diabetes mellitus, and/or heart failure, especially the elderly, a K + .5.0 mmol/L is associated with an increased risk of death. 4 Conversely, while a K + ,3.5 mmol/L is thought by many to be associated with an increase in mortality in patients with heart failure, there is evidence that a K + ,4.0 mmol/L is associated with an increase in mortality and that most deaths due to hypokalaemia in patients with heart failure occur with a K + ,4.0-3.5 mmol/L. 5, 6 Despite this evidence in patients with heart failure and/or CKD a K + ,4.0 mmol/L is often not corrected. The level of K + at which clinicians should be concerned about the risk of death in patients with hypertension both with hyperkalaemia and with hypokalaemia has received less attention, with many physicians becoming concerned only at a K + ,3.5 and .5.5 mmol/L.
In this issue of the journal, Krogager et al. 7 used the Danish National Patient Registry to examine the association between K + and all-cause mortality over 90 days in .40 000 patients with hypertension taking a dual single antihypertensive drug. Patients with renal insufficiency, those with missing serum creatinine values, as well as those who prior to the administration of two concomitant antihypertensives were diagnosed with CKD, including proteinuria or primary aldosteronism, were excluded. Co-morbid conditions such as atrial fibrillation, heart failure, and acute myocardial infarction were present at a rate of 10% each, while somewhat more than 10% of patients were receiving antidiabetic drugs. The authors found a U-shaped relationship between a K + ,4.1 and .4.7 mmol/L and all-cause mortality. After adjusting for age, sex, biologically relevant co-morbidities, and concomitant medications, as well as when patients with a history of myocardial infarction or heart failure were excluded from the analysis, the results were similar. The authors emphasize the fact that patients whose levels of K + are often considered within the normal range, from 3.5 to 3.7, 3.8 to 4.0, and 4.8 to 5.0 mmol/L, had a significant increase in mortality with hazard ratios of 1.49, 1.14, and 1.38, respectively. Several limitations of their study are noted, including: its observational nature; lack of information on the cause of death; and potential misclassification of some patients as hypertensives; and they also point out that they cannot determine whether the increase in mortality that they have observed is due to potassium's influence on the membrane potential or other processes. While future prospective studies will be required to verify the exact level of K + associated with death in a broader population of patients with hypertension, the fact remains that K + levels considered within the normal range by many clinicians, and often ignored, are associated with an increased risk of death. In view of the finding of an increase in mortality in these patients with hypertension at a K + .4.7 mmol/L within 90 days of measurement, it would seem prudent in those at risk for hyperkalaemia, such as those patients with a history of CKD, diabetes mellitus, and/or the elderly to be provided with dietary counselling regarding a low potassium diet. Many physicians do not have the knowledge or time to advise their patients properly regarding foods that have a high potassium content and should therefore routinely refer their patients with hypertension to a dietician. The DASH diet, 8 of renin -angiotensin -aldosterone system inhibitor-(RAAS-I) based strategy to a strategy not associated with hyperkalaemia such as a calcium channel blocking agent should be considered, since the evidence that a RAAS-I-based strategy is superior to other classes of antihypertensive therapy is lacking for most patients with hypertension at low cardiovascular risk and for those with diabetes mellitus. 9 If, however, hypertension is complicated by CKD and/or heart failure with a reduced left ventricular ejection fraction (HFREF), the situation is more complex in that RAAS-Is have been shown to be of benefit. Therefore, reducing the dose of the RAAS-I or discontinuing it could place the patient at increased risk for death. In this situation, one might consider the use of a K + -lowering agent while continuing a RAAS-I. Unfortunately sodium polystyrene sulphonate (SPS), an available K + -lowering agent, has been associated with an increased risk of bowel necrosis and exchanges potassium for sodium, which could increase the risk for volume overload in a patient with HFREF. 10 The recent availability, at least in the USA, of the nonabsorbed potassium-lowering polymer Patiromer and the likely availability within the year of the potassium-binding agent ZS9 provide an opportunity to maintain a RAAS-I in patients with hypertension. 11 While both Patiromer and ZS9 have been shown to be effective in reducing K + to normal levels in patients with hyperkalaemia and to be relatively well tolerated, it will be necessary to evaluate their long-term efficacy on cardiovascular outcomes while maintaining a RAAS-I in comparison with switching to another class of antihypertensive agent. It will also be important to compare the long-term efficacy and safety of Patiromer with those of ZS9 since while Patiromer exchanges potassium for calcium ZS9 exchanges potassium for sodium, raising the possibility that similarly to SPS, ZS9 could lead to an increase in sodium absorption and volume overload. The risk of death in patients with hypertension whose K + is .4.7 mmol/L may, however, in the long run be less than the risk in those in whom K + is ,4.1 -3.5 mmol/L, since many clinicians do not recognize that these patients are at an increased risk for death and become concerned only when K + is ,3.5 mmol/L. In fact, Krogager et al. 7 note their surprise in finding that these K + levels thought to be within the normal range were associated with an increased risk for death. However, one should not be surprised by these findings in view of the fact that in patients with heart failure both with and without concomitant CKD, a K + ,4.0 23.5 mmol/L has been shown to be associated with an increased risk of death. 5, 6 To avoid an increase in death in patients with hypertension who are at risk for hypokalaemia, one would recommend a diet rich in potassium, such as the DASH diet. Potassium supplements have been the usual approach to avoid and/or to correct hypokalaemia. One might, however, suggest that in the long run switching from a thiazide to a potassium-sparring diuretic such as amiloride might be as effective but with a lower risk of death. One might also rather consider the use of spironolactone (in patients with an eGFR .30 mL/min/ 1/73 m 2 ) which could not only prevent hypokalaemia but has also been shown to prevent target organ damage, including vascular stiffness which has been associated with the development of heart failure. 12 Spironolactone has been proven effective in patients with resistant hypertension, 13 and in the long run may prove to be firstor second-line therapy in patients with hypertension and the metabolic syndrome, in whom aldosterone levels are elevated, and spironolactone is effective in reducing myocardial fibrosis as well as blood pressure. 14 A potential strategy to prevent and treat both hypo-and hyperkalaemia in patients with hypertension is outlined in Figure 1 . It should, however, be emphasized that this strategy will need prospective evaluation.
In conclusion, we are indebted to Krogager et al. 7 for focusing our attention on the risks of both hyper-and hypokalaemia in patients with hypertension and pointing out that we should be concerned about K + levels currently thought by many to be within the normal range. Their study should be a 'wake-up call', prompting further studies to prevent the deviations in K + above and below the levels associated with all-cause death in patients with hypertension. While the relative risks of death related to deviations in K + within the 'normal range', both ,4.0 and .4.7 mmol/L, are relatively low, the potential absolute number of deaths is staggering given the growing incidence of hypertension in our ageing population and the recent evidence suggesting the need for more intensive blood pressure lowering. 
